The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor.

by Gerrits, C. J., Schellens, J. H., Creemers, G. J., Wissel, P., Planting, A. S., Pritchard, J. F., DePee, S., de Boer-Dennert, M., Harteveld, M., Verweij, J.
Published 1997

A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion.

by Paz-Ares, L., Kunka, R., DeMaria, D., Cassidy, J., Alden, M., Beranek, P., Kaye, S., Littlefield, D., Reilly, D., Depee, S., Wissel, P., Twelves, C., O'Dwyer, P.
Published 1998

Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration.

by Gerrits, C. J., Creemers, G. J., Schellens, J. H., Wissel, P., Planting, A. S., Kunka, R., Selinger, K., de Boer-Dennert, M., Marijnen, Y., Harteveld, M., Verweij, J.
Published 1996

Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours

by Kerklaan, B Milojkovic, Lolkema, M P J, Devriese, L A, Voest, E E, Nol-Boekel, A, Mergui-Roelvink, M, Langenberg, M, Mykulowycz, K, Stoebenau, J, Lane, S, Legenne, P, Wissel, P, Smith, D A, Giantonio, B J, Schellens, J H M, Witteveen, P O
Published 2015